Study to Determine the Safety and Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) in Patients Who Have Previously Not Received the Standard of Care

NCT01359644 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

350

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Hepatitis C

Interventions

DRUG: PSI-7977
DRUG: Daclatasvir
DRUG: Ribavirin

Sponsor

Bristol-Myers Squibb

Collaborators

[object Object]